The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) effects of VX-661 alone and when coadministered with ivacaftor in subjects with CF who are homozygous or heterozygous for the F508del-CFTR mutation.